Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1217

1.

The mechanism and function of active DNA demethylation in plants.

Liu R, Lang Z.

J Integr Plant Biol. 2019 Oct 19. doi: 10.1111/jipb.12879. [Epub ahead of print] Review.

PMID:
31628716
2.

GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors.

Richardson TE, Tang K, Vasudevaraja V, Serrano J, William CM, Mirchia K, Pierson CR, Leonard JR, AbdelBaki MS, Schieffer KM, Cottrell CE, Tovar-Spinoza Z, Comito MA, Boué DR, Jour G, Snuderl M.

J Neuropathol Exp Neurol. 2019 Sep 16. pii: nlz093. doi: 10.1093/jnen/nlz093. [Epub ahead of print]

PMID:
31626289
3.

Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report.

Fang C, Zhang C, Zhao WQ, Hu WW, Wu J, Ji M.

BMC Med Genomics. 2019 Oct 16;12(1):136. doi: 10.1186/s12920-019-0592-6.

4.

Molecular profiling in lung cancer associated with cystic airspaces.

Snoeckx A, Reyntiens P, Pauwels P, Van Schil PE, Parizel PM, Van Meerbeeck JP.

Acta Clin Belg. 2019 Oct 15:1-4. doi: 10.1080/17843286.2019.1680134. [Epub ahead of print]

PMID:
31615350
5.

ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).

Chiari R, Ricciuti B, Landi L, Morelli AM, Delmonte A, Spitaleri G, Cortinovis DL, Lamberti G, Facchinetti F, Pilotto S, Verusio C, Chella A, Bonanno L, Galetta D, Cappuzzo F.

Clin Lung Cancer. 2019 Jun 18. pii: S1525-7304(19)30154-8. doi: 10.1016/j.cllc.2019.06.012. [Epub ahead of print]

PMID:
31607443
6.

Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Garrido P, Conde E, de Castro J, Gómez-Román JJ, Felip E, Pijuan L, Isla D, Sanz J, Paz-Ares L, López-Ríos F.

Clin Transl Oncol. 2019 Oct 9. doi: 10.1007/s12094-019-02218-4. [Epub ahead of print]

PMID:
31598903
7.

Distinctive targetable genotypes of younger patients with lung adenocarcinoma: a cBioPortal for cancer genomics data base analysis.

Hou H, Zhang C, Qi X, Zhou L, Liu D, Lv H, Li T, Sun D, Zhang X.

Cancer Biol Ther. 2019 Oct 9:1-8. doi: 10.1080/15384047.2019.1665392. [Epub ahead of print]

PMID:
31594446
8.

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

Moro-Sibilot D, Cozic N, Pérol M, Mazières J, Otto J, Souquet PJ, Bahleda R, Wislez M, Zalcman G, De Guibert S, Barlési F, Mennecier B, Monnet I, Sabatier R, Bota S, Dubos C, Verriele V, Haddad V, Ferretti G, Cortot A, De Fraipont F, Jimenez M, Hoog-Labouret N, Vassal G.

Ann Oncol. 2019 Oct 4. pii: mdz407. doi: 10.1093/annonc/mdz407. [Epub ahead of print]

PMID:
31584608
9.

Diagnostic utility of pan-Trk immunohistochemistry for inflammatory myofibroblastic tumors.

Yamamoto H, Nozaki Y, Kohashi K, Kinoshita I, Oda Y.

Histopathology. 2019 Oct 3. doi: 10.1111/his.14010. [Epub ahead of print]

PMID:
31578734
10.

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date.

Facchinetti F, Friboulet L.

Lung Cancer (Auckl). 2019 Sep 9;10:87-94. doi: 10.2147/LCTT.S190786. eCollection 2019.

11.

Discovery of 2-aminopyridines bearing a pyridone moiety as potent ALK inhibitors to overcome the crizotinib-resistant mutants.

Chen W, Guo X, Zhang C, Ke D, Zhang G, Yu Y.

Eur J Med Chem. 2019 Sep 24;183:111734. doi: 10.1016/j.ejmech.2019.111734. [Epub ahead of print]

PMID:
31569004
12.

Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.

Zito Marino F, Rossi G, Cozzolino I, Montella M, Micheli M, Bogina G, Munari E, Brunelli M, Franco R.

J Clin Pathol. 2019 Sep 27. pii: jclinpath-2019-206152. doi: 10.1136/jclinpath-2019-206152. [Epub ahead of print]

PMID:
31562206
13.

Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy.

Hsieh MS, Lin MW, Lee YH.

Lung Cancer. 2019 Aug 26;137:76-84. doi: 10.1016/j.lungcan.2019.08.029. [Epub ahead of print]

PMID:
31561203
14.

Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas.

Guerreiro Stucklin AS, Ryall S, Fukuoka K, Zapotocky M, Lassaletta A, Li C, Bridge T, Kim B, Arnoldo A, Kowalski PE, Zhong Y, Johnson M, Li C, Ramani AK, Siddaway R, Nobre LF, de Antonellis P, Dunham C, Cheng S, Boué DR, Finlay JL, Coven SL, de Prada I, Perez-Somarriba M, Faria CC, Grotzer MA, Rushing E, Sumerauer D, Zamecnik J, Krskova L, Garcia Ariza M, Cruz O, Morales La Madrid A, Solano P, Terashima K, Nakano Y, Ichimura K, Nagane M, Sakamoto H, Gil-da-Costa MJ, Silva R, Johnston DL, Michaud J, Wilson B, van Landeghem FKH, Oviedo A, McNeely PD, Crooks B, Fried I, Zhukova N, Hansford JR, Nageswararao A, Garzia L, Shago M, Brudno M, Irwin MS, Bartels U, Ramaswamy V, Bouffet E, Taylor MD, Tabori U, Hawkins C.

Nat Commun. 2019 Sep 25;10(1):4343. doi: 10.1038/s41467-019-12187-5.

15.

Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.

Bebb DG, Agulnik J, Albadine R, Banerji S, Bigras G, Butts C, Couture C, Cutz JC, Desmeules P, Ionescu DN, Leighl NB, Melosky B, Morzycki W, Rashid-Kolvear F, Lab C, Sekhon HS, Smith AC, Stockley TL, Torlakovic E, Xu Z, Tsao MS.

Curr Oncol. 2019 Aug;26(4):e551-e557. doi: 10.3747/co.26.5137. Epub 2019 Aug 1.

16.

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.

Morano F, Corallo S, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Murialdo R, Zaniboni A, Sartore-Bianchi A, Tomasello G, Racca P, Clavarezza M, Adamo V, Perrone F, Gloghini A, Tamborini E, Busico A, Martinetti A, Palermo F, Loupakis F, Milione M, Fucà G, Di Bartolomeo M, de Braud F, Pietrantonio F.

J Clin Oncol. 2019 Sep 20:JCO1901254. doi: 10.1200/JCO.19.01254. [Epub ahead of print]

PMID:
31539295
17.

Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization.

Huang RSP, Smith D, Le CH, Liu WW, Ordinario E, Manohar C, Lee M, Rajamani J, Truong H, Li J, Choi C, Li J, Pati A, Bubendorf L, Buettner R, Kerr KM, Lopez-Rios F, Marchetti A, Marondel I, Nicholson AG, Öz AB, Pauwels P, Penault-Llorca F, Rossi G, Thunnissen E, Newell AH, Pate G, Menzl I.

Arch Pathol Lab Med. 2019 Sep 11. doi: 10.5858/arpa.2019-0085-OA. [Epub ahead of print]

PMID:
31509456
18.

Pathologic Characteristics of Spitz Melanoma With MAP3K8 Fusion or Truncation in a Pediatric Cohort.

Newman S, Pappo A, Raimondi S, Zhang J, Barnhill R, Bahrami A.

Am J Surg Pathol. 2019 Sep 6. doi: 10.1097/PAS.0000000000001362. [Epub ahead of print]

PMID:
31498175
19.

An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects.

Lei H, Jia F, Cao M, Wang J, Guo M, Zhu M, Zuo D, Zhai X.

Bioorg Med Chem. 2019 Oct 15;27(20):115051. doi: 10.1016/j.bmc.2019.115051. Epub 2019 Aug 21.

PMID:
31492532
20.

Characterization and fine mapping of Arabidopsis RLL3, a locus required for DNA demethylation pathway.

Miao W, Dai J, La Y, Lu C, Zhang J, Hong X, Zhou S, Wang Q, Wang X, Rui Q, Tan F, La H.

Mol Genet Genomics. 2019 Sep 5. doi: 10.1007/s00438-019-01605-4. [Epub ahead of print]

PMID:
31486938

Supplemental Content

Loading ...
Support Center